Current and future trials of targeted therapies in cutaneous melanoma

Advances in Experimental Medicine and Biology

Volumn 779, Issue , 2013, Pages 223-255

  Evans, Matthew S ^a   Madhunapantula, SubbaRao V ^b   Robertson, Gavin P ^a,b   Drabick, Joseph J ^a  

^a PENN STATE CANCER INSTITUTE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

AZD6244; Drug resistance; MAPK signaling; Melanoma; PLX 4032

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; ANTINEOPLASTIC AGENT; AURORA A KINASE; B RAF KINASE; BEVACIZUMAB; CARBOPLATIN; DABRAFENIB; DACARBAZINE; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PACLITAXEL; RAF PROTEIN; RAPAMYCIN; RAS PROTEIN; SELUMETINIB; SORAFENIB; TIPIFARNIB; TOZASERTIB; UNINDEXED DRUG; VEMURAFENIB; WORTMANNIN; XL 281;

ADVANCED CANCER; ALOPECIA; ARTHRALGIA; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CUTANEOUS MELANOMA; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; FATIGUE; HUMAN; KERATOACANTHOMA; MELANOMA; METASTASIS; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

EID: 84873589171     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-6176-0_10     Document Type: Review

References (195)

1. Rager EL, Bridgeford EP, Ollila DW. Cutaneous melanoma: Update on prevention, screening, diagnosis, and treatment. Am Fam Physician. 2005;72(2):269-76.
2. Edwards BK, Howe HL, Ries LA, Thun MJ, Rosenberg HM, Yancik R, et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer. 2002;94(10):2766-92.
3. Whiteman DC, Whiteman CA, Green AC. Childhood sun exposure as a risk factor for melanoma: A systematic review of epidemiologic studies. Cancer Causes Control. 2001;12(1):69-82.
4. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172(5):902-8.
5. NIH Consensus conference. Diagnosis and treatment of early melanoma. JAMA. 9;268(10):1314-9.
6. Balch CM, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Drzewiecki K, et al. Efficacy of 2-cm surgical margins for intermediate-Thickness melanomas (1 to 4 mm). Results of a multiinstitutional randomized surgical trial. Ann Surg. 1993;218(3):262-7. discussion 7-9
7. Veronesi U, Cascinelli N, Adamus J, Balch C, Bandiera D, Barchuk A, et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med. 1988;318(18):1159-62.
8. Veronesi U, Adamus J, Aubert C, Bajetta E, Beretta G, Bonadonna G, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med. 1982;307(15):913-6.
9. Panka DJ, Atkins MB, Mier JW. Targeting the mitogen-Activated protein kinase pathway in the treatment of malignant melanoma. Clin Cancer Res. 2006;12(7 PT2):2371s-5.
10. Lopez-Bergami P, Fitchman B, Ronai Z. Understanding signaling cascades in melanoma. Photochem Photobiol. 2008;84(2):289-306.
11. Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta. 2003;1653(1):25-40.
12. Russo AE, Torrisi E, Bevelacqua Y, Perrotta R, Libra M, McCubrey JA, et al. Melanoma: Molecular pathogenesis and emerging target therapies (review). Int J Oncol. 2009;34(6):1481-9.
13. Madhunapantula SV, Desai D, Sharma A, Huh S, Amin S, Robertson GP. PBIse, a novel selenium containing drug for the treatment of malignant melanoma. Mol Cancer Ther. 2008;7(5):1297-308.
14. Dhomen N, Marais R. BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am. 2009;23(3):529-45. ix.
15. Gollob JA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in cancer: Therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol. 2006; 33(4):392-406.
16. Fensterle J. A trip through the signaling pathways of melanoma. J Dtsch Dermatol Ges. 2006;4(3):205-17.
17. Meier F, Schittek B, Busch S, Garbe C, Smalley K, Satyamoorthy K, et al. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci. 2005;10:2986-3001.
18. Marquette A, Bagot M, Bensussan A, Dumaz N. Recent discoveries in the genetics of melanoma and their therapeutic implications. Arch Immunol Ther Exp (Warsz). 2007;55(6):363-72.
19. Tsao H, Zhang X, Fowlkes K, Haluska FG. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res. 2000;60(7):1800-4.
20. Dahl C, Guldberg P. The genome and epigenome of malignant melanoma. APMIS. 2007;115(10):1161-76.
21. Chin L, Pomerantz J, Polsky D, Jacobson M, Cohen C, Cordon-Cardo C, et al. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev. 1997;11(21):2822-34.
22. Mishra PJ, Ha L, Rieker J, Sviderskaya EV, Bennett DC, Oberst MD, et al. Dissection of RAS downstream pathways in melanomagenesis: A role for Ral in transformation. Oncogene. 2010;29(16):2449-56.
23. Ackermann J, Frutschi M, Kaloulis K, McKee T, Trumpp A, Beermann F. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res. 2005;65(10):4005-11.
24. Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, et al. Essential role for oncogenic Ras in tumour maintenance. Nature. 1999;400(6743):468-72.
25. Prendergast GC, Rane N. Farnesyltransferase inhibitors: Mechanism and applications. Expert Opin Investig Drugs. 2001;10(12):2105-16.
26. Smalley KS, Eisen TG. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-Apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. Int J Cancer. 2003; 105(2):165-75.
27. Halaschek-Wiener J, Kloog Y, Wacheck V, Jansen B. Farnesyl thiosalicylic acid chemosensitizes human melanoma in vivo. J Invest Dermatol. 2003;120(1):109-15.
28. Meier F, Niessner H, Flaherty K, Schadendorf D, Sinnberg T, Schittek B, Garbe C. Effect of the farnesyl transferase inhibitor lonafarnib on sensitivity of melanoma cells to multikinase inhibitor sorafenib and opn Rheb farnesylation and mTOR signaling. J Clin Oncol. [Abstract]. 2009;27(15S (Supplement abstract 9077).
29. End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001;61(1):131-7.
30. Sosman JA, Puzanov I. Molecular targets in melanoma from angiogenesis to apoptosis. Clin Cancer Res. 2006;12(7 PT2):2376s-83.
31. McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, et al. Emerging Raf inhibitors. Expert Opin Emerg Drugs. 2009;14(4):633-48.
32. Gajewsky T, Niedezwiecki D, Johnson J, Linette G, Bucher C, Blakovich M, et al. Phase-II study of farnesyltransferase inhibitor R115777 in advanced melanoma: CALGB500104. J Clin Oncol. [Abstract]. 2006;24(18S, June 20 Supplement, Abstract #8014).
33. Dellavalle RP, Nicholas MK, Schilling LM. Melanoma chemoprevention: A role for statins orfibrates? Am J Ther. 2003;10(3):203-10.
34. Kelland LR. Farnesyl transferase inhibitors in the treatment of breast cancer. Expert Opin Emerg Drugs. 2003;12(3):413-21.
35. Rose WC, Lee FY, Fairchild CR, Lynch M, Monticello T, Kramer RA, et al. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Res. 2001;61(20):7507-17.
36. Rose WC, Long BH, Fairchild CR, Lee FY, Kadow JF. Preclinical pharmacology of BMS-275183, an orally active taxane. Clin Cancer Res. 2001;7(7):2016-21.
37. Dinsmore CJ, Bogusky MJ, Culberson JC, Bergman JM, Homnick CF, Zartman CB, et al. Conformational restriction of fl exible ligands guided by the transferred noe experiment: Potent macrocyclic inhibitors of farnesyltransferase. J Am Chem Soc. 2001;123(9):2107-8.
38. Camacho LH SS, Pezzulli S, et al. Dose escalation study of oral farnesyl transferase inhibitor (FTI) BMS-214662 in patients with solid tumors. Proc Annu Meet Am Soc Clin Oncol. 2001;20:311 [Abstract].
39. Rubin EAJ, Morrison BW, et al. Phase I trial of the farnesyl protein transferase inhibitor L-778123 on 14- or 28-day dosing schedule. Proc Annu Meet Am Soc Clin Oncol. 2000;19:689 [Abstract].
40. Sharma SBC, Spriggs D, et al. A Phase I trial and PK study of farnesyl transferase inhibitor L-778123 administered as a seven day continuous infusion in combination with paclitaxel. Proc Annu Meet Am Soc Clin Oncol. 2000;19:719 [Abstract].
41. Hahn SMKK, Morrison BW, et al. Phase I trial of farnesyl transferase inhibitor L-778123 in combination with radio-Therapy. Proc Annu Meet Am Soc Clin Oncol. 2000;19:906 [Abstract].
42. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst. 2001;93(14):1062-74.
43. Brummer T, Martin P, Herzog S, Misawa Y, Daly RJ, Reth M. Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein. Oncogene. 2006;25(47):6262-76.
44. Rajakulendran T, Sahmi M, Lefrancois M, Sicheri F, Therrien M. A dimerization-dependent mechanism drives RAF catalytic activation. Nature. 2009;461(7263):542-5.
45. Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 2004;5(11):875-85.
46. Michaloglou C, Vredeveld LC, Mooi WJ, Peeper DS. BRAF(E600) in benign and malignant human tumours. Oncogene. 2008;27(7):877-95.
47. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-54.
48. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhonen S, et al. BRAF mutations in metastatic melanoma: A possible association with clinical outcome. Clin Cancer Res. 2003;9(9):3362-8.
49. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell. 2004;6(4):313-9.
50. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855-67.
51. Wellbrock C, Ogilvie L, Hedley D, Karasarides M, Martin J, Niculescu-Duvaz D, et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res. 2004;64(7):2338-42
52. Tuveson DA, Weber BL, Herlyn M. BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell. 2003;4(2):95-8.
53. Hoe fl ich KP, Gray DC, Eby MT, Tien JY, Wong L, Bower J, et al. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res. 2006;66(2):999-1006.
54. Liang S, Sharma A, Peng HH, Robertson G, Dong C. Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation. Cancer Res. 2007;67(12):5814-20.
55. Sharma A, Tran MA, Liang S, Sharma AK, Amin S, Smith CD, et al. Targeting mitogen-Activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res. 2006;66(16):8200-9.
56. Boyle GM, Pedley J, Martyn AC, Banducci KJ, Strutton GM, Brown DA, et al. Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity. J Invest Dermatol. 2009;129(2):383-91.
57. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 2005;65(6):2412-21.
58. Cheung M, Sharma A, Madhunapantula SV, Robertson GP. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res. 2008;68(9):3429-39.
59. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell. 2008;132(3):363-74.
60. Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell. 2009;15(4):294-303.
61. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, et al. BRAFE600-Associated senescence-like cell cycle arrest of human naevi. Nature. 2005;436(7051):720-4.
62. Nguyen LP, Emley A, Wajapeyee N, Green MR, Mahalingam M. BRAF V600E mutation and the tumour suppressor IGFBP7 in atypical genital naevi. Br J Dermatol. 2009;162(3):677-80.
63. Zhao Y, Zhang Y, Yang Z, Li A, Dong J. Simultaneous knockdown of BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition and apoptosis. Biochem Biophys Res Commun. 2008;370(3):509-13.
64. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky Jr. WE, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 2009;41(5):544-52.
65. Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD, et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol. 2005;15(3):249-54.
66. Yu H, McDaid R, Lee J, Possik P, Li L, Kumar SM, et al. The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes. Am J Pathol. 2009;174(6):2367-77.
67. Gallagher SJ, Thompson JF, Indsto J, Scurr LL, Lett M, Gao BF, et al. p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors. Neoplasia. 2008;10(11):1231-9.
68. Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol. 2006;126(1):154-60.
69. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099-109.
70. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, et al. Sorafenib in advanced melanoma: A phase II randomised discontinuation trial analysis. Br J Cancer. 2006;95(5):581-6.
71. Takimoto CH, Awada A. Safety and anti-Tumor activity of sorafenib (nexavar) in combination with other anti-cancer agents: A review of clinical trials. Cancer Chemother Pharmacol. 2008;61(4):535-48.
72. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, et al. B-RAF is a therapeutic target in melanoma. Oncogene. 2004;23(37):6292-8.
73. Madhunapantula SV, Robertson GP. Is B-Raf a good therapeutic target for melanoma and other malignancies? Cancer Res. 2008;68(1):5-8.
74. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA. 2008;105(8):3041-6.
75. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467(7315):596-9.
76. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-19.
77. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-16.
78. Hong S, Han SB. Overcoming metastatic melanoma with BRAF inhibitors. Arch Pharm Res. 2011;34(5):699-701.
79. Agarwala SS, di Pietro A, Flaherty KT, Garbe C, Grob JJ, Kashani-Sabet M, et al. Meeting report from the third global workshop on melanoma. Pigment Cell Melanoma Res. 2010;23(5):e1-7.
80. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973-7.
81. Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med. 2011;364(8):772-4.
82. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468(7326):968-72. Dec 16 2010.
83. Kaplan FM, Shao Y, Mayberry MM, Aplin AE. Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells. Oncogene. 2011;30(3):366-71.
84. Brower V. BRAF inhibitors: Research accelerates in wake of positivefindings. J Natl Cancer Inst. 2010;102(4):214-5.
85. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439(7074):358-62.
86. Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-Activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: Mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther. 2007;6(8):2209-19.
87. Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-Activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.
88. Daouti S, Higgins B, Kolinsky K, Packman K, Wang H, Rizzo C, et al. Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor models. Mol Cancer Ther. 2010;9(1):134-44.
89. Mandic A, Viktorsson K, Heiden T, Hansson J, Shoshan MC. The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis. Melanoma Res. 2001;11(1):11-9.
90. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.
91. Lopez-Bergami P, Huang C, Goydos JS, Yip D, Bar-Eli M, Herlyn M, et al. Rewired ERKJNK signaling pathways in melanoma. Cancer Cell. 2007;11(5):447-60.
92. Mirmohammadsadegh A, Mota R, Gustrau A, Hassan M, Nambiar S, Marini A, et al. ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatinmediated apoptosis. J Invest Dermatol. 2007;127(9):2207-15. Current and Future Trials of Targeted Therapies in Cutaneous Melanoma 2511
93. Pardo OE, Arcaro A, Salerno G, Tetley TD, Valovka T, Gout I, et al. Novel cross talk between MEK and S6K2 in FGF-2 induced proliferation of SCLC cells. Oncogene. 2001;20(52):7658-67.
94. Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Palmer AA, Zhang XD, et al. Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. J Clin Pathol. 2005;58(11):1163-9.
95. Kohno MJP. Pharmacological inhibitors of the ERK signaling pathway: Applications as anticancer drugs. Prog Cell Cycle Res. 2003;5(Chapter 22):219-24.
96. Boss DS, Beijnen JH, Schellens JH. Clinical experience with aurora kinase inhibitors: A review. Oncologist. 2009;14(8):780-93.
97. Carmena M, Ruchaud S, Earnshaw WC. Making the Auroras glow: Regulation of Aurora A and B kinase function by interacting proteins. Curr Opin Cell Biol. 2009;21(6):796-805.
98. Libertini S, Abagnale A, Passaro C, Botta G, Portella G. Aurora A and B kinases - Targets of novel anticancer drugs. Recent Pat Anticancer Drug Discov. 2010;5(3):219-41.
99. Kollareddy M, Dzubak P, Zheleva D, Hajduch M. Aurora kinases: Structure, functions and their association with cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008;152(1):27-33.
100. Macarulla T, Ramos FJ, Tabernero J. Aurora kinase family: A new target for anticancer drug. Recent Pat Anticancer Drug Discov. 2008;3(2):114-22.
101. Vader G, Lens SM. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta. 2008;1786(1):60-72.
102. Barr AR, Gergely F. Aurora-A: The maker and breaker of spindle poles. J Cell Sci. 2007;120(PT17):2987-96.
103. Cimini D. Detection and correction of merotelic kinetochore orientation by Aurora B and its partners. Cell Cycle. 2007;6(13):1558-64.
104. Yeung SC, Gully C, Lee MH. Aurora-B kinase inhibitors for cancer chemotherapy. Mini Rev Med Chem. 2008;8(14):1514-25.
105. Dar AA, Goff LW, Majid S, Berlin J, El-Rifai W. Aurora kinase inhibitors - rising stars in cancer therapeutics? Mol Cancer Ther. 2010;9(2):268-78.
106. Saeki T, Ouchi M, Ouchi T. Physiological and oncogenic Aurora-A pathway. Int J Biol Sci. 2009;5(7):758-62.
107. Ju H, Cho H, Kim YS, Kim WH, Ihm C, Noh SM, et al. Functional polymorphism 57Val>Ile of aurora kinase A associated with increased risk of gastric cancer progression. Cancer Lett. 2006;242(2):273-9.
108. Tchatchou S, Wirtenberger M, Hemminki K, Sutter C, Meindl A, Wappenschmidt B, et al. Aurora kinases A and B and familial breast cancer risk. Cancer Lett. 2007;247(2):266-72.
109. Ewart-Toland A, Dai Q, Gao YT, Nagase H, Dunlop MG, Farrington SM, et al. Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: A meta-Analysis of multiple cancer types. Carcinogenesis. 2005;26(8):1368-73.
110. Arbitrario JP, Belmont BJ, Evanchik MJ, Flanagan WM, Fucini RV, Hansen SK, et al. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-Tumor activity and dosing fl exibility in vivo. Cancer Chemother Pharmacol. 2010;65(4):707-17.
111. Katayama H, Sen S. Aurora kinase inhibitors as anticancer molecules. Biochim Biophys Acta. 2010;1799(10-12):829-39.
112. Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer. 2010;10(12):825-41.
113. Pirker C, Lotsch D, Spiegl-Kreinecker S, Jantscher F, Sutterluty H, Micksche M, et al. Response of experimental malignant melanoma models to the pan-Aurora kinase inhibitor VE-465. Exp Dermatol. 2010;19(12):1040-7.
114. Dees EC, Infante JR, Cohen RB, O'Neil BH, Jones S, von Mehren M, et al. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2010;67(4):945-54.
115. Macarulla T, Cervantes A, Elez E, Rodriguez-Braun E, Baselga J, Rosello S, et al. Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: Safety, pharmacokinetics, and pharmacodynamics. Mol Cancer Ther. 2010;9(10):2844-52.
116. Carol H, Boehm I, Reynolds CP, Kang MH, Maris JM, Morton CL, et al. Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol. 2011;68(5):1291-304.
117. Yamashita T, Yoneta A, Hida T. Macrophage inhibitory cytokine-1: A new player in melanoma development. J Invest Dermatol. 2009;129(2):262-4.
118. Huh SJ, Chung CY, Sharma A, Robertson GP. Macrophage inhibitory cytokine-1 regulates melanoma vascular development. Am J Pathol. 2010;176(6):2948-57.
119. Singh RK, Varney ML. IL-8 expression in malignant melanoma: Implications in growth and metastasis. Histol Histopathol. 2000;15(3):843-9.
120. Zhang H, Fu T, McGettigan S, Kumar S, Liu S, Speicher D, et al. IL8 And cathepsin B as melanoma serum biomarkers. Int J Mol Sci. 2011;12(3):1505-18.
121. Jovanovic M, Stefanoska I, Radojcic L, Vicovac L. Interleukin-8 (CXCL8) stimulates trophoblast cell migration and invasion by increasing levels of matrix metalloproteinase (MMP)2 and MMP9 and integrins alpha5 and beta1. Reproduction. 2010;139(4):789-98.
122. Araki K, Shimura T, Yajima T, Tsutsumi S, Suzuki H, Okada K, et al. Phosphoglucose isomerase/autocrine motility factor promotes melanoma cell migration through ERK activation dependent on autocrine production of interleukin-8. J Biol Chem. 2009;284(47): 32305-11.
123. Huh SJ, Liang S, Sharma A, Dong C, Robertson GP. Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development. Cancer Res. 2010;70(14):6071-82.
124. Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, et al. Tumor selfseeding by circulating cancer cells. Cell. 2009;139(7):1315-26.
125. Crawford S, Belajic D, Wei J, Riley JP, Dunford PJ, Bembenek S, et al. A novel B-RAF inhibitor blocks interleukin-8 (IL-8) synthesis in human melanoma xenografts, revealing IL-8 as a potential pharmacodynamic biomarker. Mol Cancer Ther. 2008;7(3):492-9.
126. Ciuffreda L, Del Bufalo D, Desideri M, Di Sanza C, Stoppacciaro A, Ricciardi MR, et al. Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia. 2009;11(8):720-31.
127. Oka M, Sakaguchi M, Okada T, Nagai H, Ozaki M, Yoshioka T, et al. Signal transducer and activator of transcription 3 upregulates interleukin-8 expression at the level of transcription in human melanoma cells. Exp Dermatol. 2010;19(8):e50-5.
128. Villares GJ, Zigler M, Wang H, Melnikova VO, Wu H, Friedman R, et al. Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-Activated receptor-1 small interfering RNA. Cancer Res. 2008;68(21):9078-86.
129. Lev DC, Ruiz M, Mills L, McGary EC, Price JE, Bar-Eli M. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: A possible escape mechanism from chemotherapy. Mol Cancer Ther. 2003;2(8):753-63.
130. Lev DC, Onn A, Melinkova VO, Miller C, Stone V, Ruiz M, et al. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol. 2004;22(11):2092-100.
131. Chung CY, Madhunapantula SV, Desai D, Amin S, Robertson GP. Melanoma prevention using topical PBISe. Cancer Prev Res (Phila Pa). 2011;4(6):935-48.
132. Huang S, Mills L, Mian B, Tellez C, McCarty M, Yang XD, et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol. 2002;161(1):125-34.
133. Zigler M, Villares GJ, Lev DC, Melnikova VO, Bar-Eli M. Tumor immunotherapy in melanoma: Strategies for overcoming mechanisms of resistance and escape. Am J Clin Dermatol. 2008;9(5):307-11.
134. Murrow LM, Garimella SV, Jones TL, Caplen NJ, Lipkowitz S. Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome. Breast Cancer Res Treat. 2010;122(2):347-57.
135. Walter SA, Guadagno SN, Ferrell Jr. JE. Activation of Wee1 by p42 MAPK in vitro and in cycling xenopus egg extracts. Mol Biol Cell. 2000;11(3):887-96.
136. De Witt Hamer PC, Mir SE, Noske D, Van Noorden CJ, Wurdinger T. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. Clin Cancer Res. 2011;17:4200-7.
137. Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N, et al. MK-1775, a small molecule Wee1 inhibitor, enhances anti-Tumor efficacy of various DNA-damaging agents, including 5- fl uorouracil. Cancer Biol Ther. 2010;9(7):514-22.
138. Smaill JB, Lee HH, Palmer BD, Thompson AM, Squire CJ, Baker EN, et al. Synthesis and structure-Activityrelationshipsofsoluble8-substituted4-(2- chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of the Wee1 and Chk1 checkpoint kinases. Bioorg Med Chem Lett. 2008;18(3):929-33.
139. Wang Y, Li J, Booher RN, Kraker A, Lawrence T, Leopold WR, et al. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res. 2001;61(22):8211-7.
140. Hashimoto O, Shinkawa M, Torimura T, Nakamura T, Selvendiran K, Sakamoto M, et al. Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyrimidine, in the B16 mouse melanoma cell line. BMC Cancer. 2006;6:292.
141. Park K, Lee MY, Kim KS, Hahn SK. Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate. Biomaterials. 2010;31(19):5258-65.
142. Molhoek KR, Griesemann H, Shu J, Gershenwald JE, Brautigan DL, Slingluff Jr. CL. Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2. Cancer Res. 2008;68(11):4392-7.
143. Yang L, Chen G, Mohanty S, Scott G, Fazal F, Rahman A, et al. GPR56 regulates VEGF production and angiogenesis during melanoma progression. Cancer Res. 2011;71(16):5558-68.
144. Akula SM, Ford PW, Whitman AG, Hamden KE, Bryan BA, Cook PP, et al. B-Raf-dependent expression of vascular endothelial growth factor-A in Kaposi sarcoma-Associated herpesvirus-infected human B cells. Blood. 2005;105(11):4516-22.
145. Niers TM, Richel DJ, Meijers JC, Schlingemann RO. Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker. PLoS One. 2011;6(5): E19873.
146. Corrie PG, Basu B, Zaki KA. Targeting angiogenesis in melanoma: Prospects for the future. Ther Adv Med Oncol. 2010;2(6):367-80.
147. Kelly RJ, Rixe O. Axitinib (AG-013736). Recent Results Cancer Res. 2010;184:33-44.
148. Choueiri TK. Axitinib, a novel anti-Angiogenic drug with promising activity in various solid tumors. Curr Opin Investig Drugs. 2008;9(6):658-71.
149. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, et al. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 2002;99(17):11393-8.
150. Hu R, Aplin AE. AlphaB-crystallin is mutant B-RAF regulated and contributes to cyclin D1 turnover in melanocytic cells. Pigment Cell Melanoma Res. 2010;23:201-9.
151. Oba J, Nakahara T, Abe T, Hagihara A, Moroi Y, Furue M. Expression of c-Kit, p-ERK and cyclin D1 in malignant melanoma: An immunohistochemical study and analysis of prognostic value. J Dermatol Sci. 2011;62(2):116-23.
152. Lebe B, Pabuccuoglu U, Ozer E. The significance of Ki-67 proliferative index and cyclin D1 expression of dysplastic nevi in the biologic spectrum of melanocytic lesions. Appl Immunohistochem Mol Morphol. 2007;15(2):160-4.
153. Joshi KS, Rathos MJ, Mahajan P, Wagh V, Shenoy S, Bhatia D, et al. P276-00, a novel cyclindependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007;6(3):926-34.
154. Mandara M, Nortilli R, Sava T, Cetto GL. Chemotherapy for metastatic melanoma. Expert Rev Anticancer Ther. 2006;6(1):121-30.
155. Huncharek M, Caubet JF, McGarry R. Single-Agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: A meta-Analysis of 3273 patients from 20 randomized trials. Melanoma Res. 2001;11(1):75-81.
156. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther. 2006;5(5):1136-44.
157. Tran MA, Gowda R, Sharma A, Park EJ, Adair J, Kester M, et al. Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Res. 2008;68(18):7638-49.
158. Meier FE, Lasithiotakis K, Schittek B, Sinnberg T, Garbe C. Temozolomide combined with the PI3K inhibitor LY294002 or the mTOR inhibitor rapamycin inhibits melanoma cell growth, survival and invasion. J Clin Oncol. [Abstract]. 2007;25(18S (June 20 Suppl) Abstract 8559).
159. Li J, Xu M, Yang Z, Li A, Dong J. Simultaneous inhibition of MEK and CDK4 leads to potent apoptosis in human melanoma cells. Cancer Invest. 2009;28(4):350-6.
160. Meier F, Busch S, Lasithiotakis K, Kulms D, Garbe C, Maczey E, et al. Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br J Dermatol. 2007;156(6):1204-13.
161. Villanueva J, Herlyn M. Melanoma and the tumor microenvironment. Curr Oncol Rep. 2008;10(5):439-46.
162. Flach EH, Rebecca VW, Herlyn M, Smalley KS, Anderson AR. Fibroblasts contribute to melanoma tumor growth and drug resistance. Mol Pharm. 2011;8(6):2039-49.
163. Dong C, Slattery MJ, Liang S, Peng HH. Melanoma cell extravasation under fl ow conditions is modulated by leukocytes and endogenously produced interleukin 8. Mol Cell Biomech. 2005;2(3):145-59.
164. Liang S, Hoskins M, Dong C. Tumor cell extravasation mediated by leukocyte adhesion is shear rate dependent on IL-8 signaling. Mol Cell Biomech. 2010;7(2):77-91.
165. Ozdemir T, Zhang P, Fu C, Dong C. Fibrin serves as a divalent ligand that regulates neutrophil-mediated melanoma cells adhesion to endothelium under shear conditions. Am J Physiol Cell Physiol. 2012;302(8):C1189-201.
166. Zhang P, Ozdemir T, Chung CY, Robertson GP, Dong C. Sequential binding of alphaVbeta3 and ICAM-1 determinesfibrin-mediated melanoma capture and stable adhesion to CD11b/CD18 on neutrophils. J Immunol. 2011;186(1):242-54.
167. Dong C, Robertson GP. Immunoediting of leukocyte functions within the tumor microenvironment promotes cancer metastasis development. Biorheology. 2009;46(4):265-79.
168. Liang S, Seto EY, Remais JV, Zhong B, Yang C, Hubbard A, et al. Environmental effects on parasitic disease transmission exemplified by schistosomiasis in western China. Proc Natl Acad Sci USA. 2007;104(17):7110-5.
169. van Kempen LC, Rijntjes J, Mamor-Cornelissen I, Vincent-Naulleau S, Gerritsen MJ, Ruiter DJ, et al. Type I collagen expression contributes to angiogenesis and the development of deeply invasive cutaneous melanoma. Int J Cancer. 2008;122(5):1019-29.
170. Huh SJ, Chen YL, Friedman SL, Liao J, Huang HJ, Cavenee WK, et al. KLF6 gene and early melanoma development in a collagen I-rich extracellular environment. J Natl Cancer Inst. 2010;102(15):1131-47.
171. Denkert C, Kobel M, Berger S, Siegert A, Leclere A, Trefzer U, et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res. 2001;61(1):303-8.
172. Goulet AC, Einsphar JG, Alberts DS, Beas A, Burk C, Bhattacharyya A, et al. Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression. Cancer Biol Ther. 2003;2(6):713-8.
173. Becker MR, Siegelin MD, Rompel R, Enk AH, Gaiser T. COX-2 expression in malignant melanoma: A novel prognostic marker? Melanoma Res. 2009;19(1):8-16.
174. Flockhart RJ, Armstrong JL, Reynolds NJ, Lovat PE. NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma. Br J Cancer. 2009;101(8):1448-55.
175. Kuzbicki L, Sarnecka A, Chwirot BW. Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression. Melanoma Res. 2006;16(1):29-36.
176. Valcarcel M, Mendoza L, Hernandez JJ, Carrascal T, Salado C, Crende O, et al. Vascular endothelial growth factor regulates melanoma cell adhesion and growth in the bone marrow microenvironment via tumor cyclooxygenase-2. J Transl Med. 2011;9:142. Current and Future Trials of Targeted Therapies in Cutaneous Melanoma 2555
177. Wilson KS. Cyclooxygenase-2 inhibition and regression of metastatic melanoma. Melanoma Res. 2006;16(5):465.
178. Goldberg GM, Rubenstone AI, Saphir O. A study of malignant lymphomas and leukemias. III. Stem cell, blast cell, and monocytic leukemias (with reference to their lymphogenous or myelogenous origin). Cancer. 1961;14:21-9.
179. Soltanian S, Matin MM. Cancer stem cells and cancer therapy. Tumour Biol. 2011;32(3): 425-40.
180. Schatton T, Frank MH. Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res. 2008;21(1):39-55.
181. Menaa F, Houben R, Eyrich M, Broecker EB, Becker JC, Wischhusen J. Stem cells, melanoma and cancer stem cells: The good, the bad and the evil? G Ital Dermatol Venereol. 2009;144(3):287-96.
182. Mimeault M, Hauke R, Mehta PP, Batra SK. Recent advances in cancer stem/progenitor cell research: Therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med. 2007;11(5):981-1011.
183. Zabierowski SE, Fukunaga-Kalabis M, Li L, Herlyn M. Dermis-derived stem cells: A source of epidermal melanocytes and melanoma? Pigment Cell Melanoma Res. 2011;24(3):422-9.
184. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005;65(20):9328-37.
185. Kumar SM, Zhang G, Bastian BC, Arcasoy MO, Karande P, Pushparajan A, et al. Erythropoietin receptor contributes to melanoma cell survival in vivo. Oncogene. 2012;31(13):1649-60.
186. Tran MA, Watts RJ, Robertson GP. Use of liposomes as drug delivery vehicles for treatment of melanoma. Pigment Cell Melanoma Res. 2009;22(4):388-99.
187. Basu S, Harfouche R, Soni S, Chimote G, Mashelkar RA, Sengupta S. Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy. Proc Natl Acad Sci USA. 2009;106(19):7957-61.
188. Fink W, Zimpfer-Rechner C, Thoelke A, Figl R, Kaatz M, Ugurel S, et al. Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma. Onkologie. 2004;27(6):540-4.
189. Hughes GA. Nanostructure-mediated drug delivery. Nanomedicine. 2005;1(1):22-30.
190. Tran MA, Smith CD, Kester M, Robertson GP. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin Cancer Res. 2008;14(11):3571-81.
191. Hwang TL, Lee WR, Hua SC, Fang JY. Cisplatin encapsulated in phosphatidylethanolamine liposomes enhances the in vitro cytotoxicity and in vivo intratumor drug accumulation against melanomas. J Dermatol Sci. 2007;46(1):11-20.
192. Bawa R. Nanoparticle-based therapeutics in humans: A survey. Nanotechnol Law Bus. 2008;5(2):135-55.
193. Yih TC, Al-Fandi M. Engineered nanoparticles as precise drug delivery systems. J Cell Biochem. 2006;97(6):1184-90.
194. Fulmer T. Curiously strong lipidoids. Science-Business exchange, "Cover story: Targets and mechanisms" featured in nature. Nature. 2010;3(2):1-2.
195. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010;464(7291):1067-70.